Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN) in a report released on Saturday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners restated a “buy” rating on shares of Evogene in a research note on Friday, March 7th.

Evogene Price Performance

NASDAQ EVGN opened at $0.97 on Friday. The firm’s fifty day moving average price is $1.31 and its 200 day moving average price is $1.66. The company has a market capitalization of $5.20 million, a price-to-earnings ratio of -0.22 and a beta of 1.37. Evogene has a 12 month low of $0.95 and a 12 month high of $9.00.

Evogene (NASDAQ:EVGN) last announced its earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.78. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. The business had revenue of $1.61 million for the quarter, compared to analyst estimates of $3.63 million. During the same period last year, the firm posted ($1.30) earnings per share.

Institutional Trading of Evogene

An institutional investor recently bought a new position in Evogene stock. Citadel Advisors LLC acquired a new stake in Evogene Ltd. (NASDAQ:EVGN) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned 0.30% of Evogene as of its most recent SEC filing. 10.40% of the stock is currently owned by institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.